impact factor
logo
 

C. Pharmacoeconomic considerations

 

Interest of modelling in rheumatoid arthritis


, , ,

 

CER5994
2012 Vol.30, N°4 ,Suppl.73
PI 0096, PF 0101
C. Pharmacoeconomic considerations

Free to view
(click on article PDF icon to read the article)

PMID: 23078913 [PubMed]

Received: 14/09/2012
Accepted : 19/09/2012
In Press: 18/10/2012
Published: 20/11/2012

Abstract

Such as prospective studies can provide evidence-based information for clinicians and regulatory agencies, modelling studies provide useful information when experimental studies are to complex, too long, or too expensive to carry out. If modelling has been widely used in pharmacokinetics, it is in the field of pharmacoeconomics that numerous models have been published in recent years, including models relevant to the management of rheumatoid arthritis (RA). The most common modelling techniques published in RA are decision trees and Markov models which are used to perform cost-effectiveness and cost-utility analyses using real or simulated populations. This paper reviews the main types of modelling techniques used in pharmacoeconomic studies with the aim of clarifying their interest and limitations for the clinicians. Generating such evidence is highly relevant to assisting clinical recommendations and reimbursement decisions towards enabling the optimal management of RA and reducing its overall clinical and economic burden, for the benefits of patients and health systems.

Rheumatology Article